Core Insights - Polyrizon Ltd. announced positive results from a pre-clinical study evaluating its PL-14 Allergy Blocker formulation, demonstrating its effectiveness in blocking allergens compared to hydroxypropyl methylcellulose (HPMC) [1][5]. Study Findings - The study utilized a validated in-vitro Transwell permeability system to assess PL-14's ability to inhibit the transfer of Der p 1, a significant house dust mite allergen associated with allergic rhinitis and asthma [2]. - PL-14 significantly reduced allergen transfer at all time points compared to HPMC, with statistical significance (p-values ≤ 0.0042) observed at 1, 2, 4, 6, and 24 hours [3][9]. - At 1 hour, PL-14 showed a mean allergen concentration of approximately 20.6 ng, while HPMC had a concentration of about 1354.4 ng. By 24 hours, HPMC's concentration rose to around 5201.2 ng, indicating limited barrier function [9]. Product Development - The results support the continued advancement of PL-14 as a preventive approach for allergic rhinitis by reducing allergen penetration through a synthetic surface [6]. - Polyrizon is advancing its preclinical development program and plans to support future clinical studies to establish PL-14's regulatory pathway and clinical benefits for allergy prevention [6]. Company Overview - Polyrizon is a development-stage biotechnology company focused on innovative medical device hydrogels delivered as nasal sprays, creating a barrier against viruses and allergens [7]. - The company's proprietary Capture and Contain TM hydrogel technology aims to function as a "biological mask" in the nasal cavity, with ongoing development to enhance bioadhesion and retention for drug delivery [7].